EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access

Evaluation of Early Tocilizumab Effect on Multiorgan Dysfunction in Critically Ill Patients With COVID-19: A Propensity Score-Matched Study

Ohoud Aljuhani, Ghazwa B Korayem, Ali F Altebainawi, Abdullah Al Harthi, Hisham A Badreldin, Muath A Alsalloum, Khalid Eljaaly, Aisha Alharbi, Rowina Aljehani, Ramesh Vishwakarma, Abeer A Alenazi, Mai Alalawi und 11 weitere

Journal of Intensive Care Medicine · 2023

DOI: 10.1177/08850666221150886 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Journal of Intensive Care Medicine, 2023. Verfasst von Ohoud Aljuhani und 22 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy Practice, Faculty of Pharmacy, King Abdulaziz University, Jeddah, Saudi Arabia. Hauptthemen laut MEDLINE: COVID-19. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Princess Nourah Bint Abdulrahman University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Tocilizumab (TCZ) has been proposed as potential rescue therapy for severe COVID-19. No previous study has primarily assessed the role of TCZ in preventing severe COVID-19-related multiorgan dysfunction. Hence, this multicenter cohort study aimed to evaluate the effectiveness of TCZ early use versus standard of care in preventing severe COVID-19-related multiorgan dysfunction in COVID-19 critically ill patients during intensive care unit (ICU) stay.

Methods

A multicenter, retrospective cohort study includes critically ill adult patients with COVID-19 admitted to the ICUs. Patients were categorized into two groups, the treatment group includes patients who received early TCZ therapy within 24 hours of ICU admission and the control group includes patients who received standard of care. The primary outcome was the multiorgan dysfunction on day three of the ICU admission. The secondary outcomes were 30-day, and in-hospital mortality, ventilator-free days, hospital length of stay (LOS), ICU LOS, and ICU-related complications.

Results

After propensity score matching, 300 patients were included in the analysis based on predefined criteria with a ratio of 1:2. Patients who received TCZ had lower multiorgan dysfunction score on day three of ICU admission compared to the control group (beta coefficient: −0.13, 95% CI: −0.26, −0.01, P-value = 0.04). Moreover, respiratory failure requiring MV was statistically significantly lower in patients who received early TCZ compared to the control group (OR 0.52; 95% CI 0.31, 0.91, P-value = 0.02). The 30-day and in-hospital mortality were significantly lower in patients who received TCZ than those who did not (HR 0.56; 95% CI 0.37, 0.85, P-value = 0 .006 and HR 0.54; 95% CI 0.36, 0.82, P-value = 0.003, respectively).

Conclusion

In addition to the mortality benefits associated with early TCZ use within 24 hours of ICU admission, the use of TCZ was associated with a significantly lower multiorgan dysfunction score on day three of ICU admission in critically ill patients with COVID-19.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19AdultHumansSARS-CoV-2Retrospective StudiesCohort StudiesCritical IllnessPropensity ScoreCOVID-19 Drug TreatmentIntensive Care UnitsAntibodies, Monoclonal, Humanized

Stichwörter der Autor:innen

COVID-19IL-6 inhibitorsSARS-CoV-2acute kidney injurycritically illintensive care units (ICUs)liver injurymortalitymultiorgan dysfunctiontocilizumab

Substanzen

tocilizumabAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Department of Pharmacy Practice, Faculty of Pharmacy, King Abdulaziz University, Jeddah, Saudi Arabia.
  • Department of Pharmacy Practice, College of Pharmacy, Princess Nourah bint Abdulrahman University, Riyadh, Saudi Arabia.
  • Pharmaceutical Care Services, King Salman Specialist Hospital, Hail Health Cluster, Ministry of Health, Hail, Saudi Arabia.
  • Pharmaceutical Care Department, King Abdulaziz Medical City, Riyadh, Saudi Arabia.
  • King Abdullah International Medical Research Center, Riyadh, Saudi Arabia.
  • College of Pharmacy, King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia.

ORCID-Profile: Khalid Al Sulaiman

Förderung

  • Princess Nourah Bint Abdulrahman University

Zitieren

APA

Aljuhani, O., Korayem, G. B., Altebainawi, A. F., Al Harthi, A., Badreldin, H. A., Alsalloum, M. A., Eljaaly, K., Alharbi, A., Aljehani, R., Vishwakarma, R., Alenazi, A. A., Alalawi, M., Alissa, A., Al Aamer, K., Al Enazi, H., Almusallam, M., Alshehri, A., Bukhari, R., Alasmari, G., …, & Al Sulaiman, K. (2023). Evaluation of Early Tocilizumab Effect on Multiorgan Dysfunction in Critically Ill Patients With COVID-19: A Propensity Score-Matched Study. Journal of Intensive Care Medicine. https://doi.org/10.1177/08850666221150886

Vancouver

Aljuhani O, Korayem GB, Altebainawi AF, Al Harthi A, Badreldin HA, Alsalloum MA, et al. Evaluation of Early Tocilizumab Effect on Multiorgan Dysfunction in Critically Ill Patients With COVID-19: A Propensity Score-Matched Study. Journal of Intensive Care Medicine. 2023. doi:10.1177/08850666221150886

BibTeX
@article{Aljuhani2023,
  author = {Aljuhani, Ohoud and Korayem, Ghazwa B and Altebainawi, Ali F and Al Harthi, Abdullah and Badreldin, Hisham A and Alsalloum, Muath A and Eljaaly, Khalid and Alharbi, Aisha and Aljehani, Rowina and Vishwakarma, Ramesh and Alenazi, Abeer A and Alalawi, Mai and Alissa, Abdulrahman and Al Aamer, Kholoud and Al Enazi, Huda and Almusallam, Mohammed and Alshehri, Abdulaziz and Bukhari, Rawan and Alasmari, Ghaday and AlQahtani, Maha M and Al Shammari, Sultanah and Alsulaymi, Hatim O and Al Sulaiman, Khalid},
  title = {Evaluation of Early Tocilizumab Effect on Multiorgan Dysfunction in Critically Ill Patients With COVID-19: A Propensity Score-Matched Study},
  journal = {Journal of Intensive Care Medicine},
  year = {2023},
  doi = {10.1177/08850666221150886}
}
Kostenlos starten →